Biotechs Presenting at the J.P. Morgan Healthcare Conference: Day Two

Loading...
Loading...
The J.P. Morgan Healthcare Conference is from January 12-15. This healthcare conference is one of the largest and most important conferences for biotech companies all year. January 13 is Day Two for the conference and a number of biotech companies will make presentations. Some of these companies will also have question and answer sessions after their presentation. Here are some key times that select biotech companies are presenting today. The conference is in San Francisco; so all times are in Pacific Standard Time. 7:30 AM: Alkermes (ALKS) 8:00 AM: Orexigen Therapeutics (OREX) 8:30 AM: Gilead Sciences (GILD) 9:00 AM: ImmunoGen (IMGN), Express Scripts (ESRX), Bristol-Myers Squibb (BMY), Boston Scientific (BSX) 9:30 AM: Amgen (AMGN) 10:00 AM: Ultragenyx Pharmaceutical (RARE) 10:30 AM: Regeneron Pharmaceutical (REGN), Amicus Therapeutics (FOLD), Catalent (CTLT) 11:00 AM: Nektar Therapeutics (NKTR) 11:30 AM: Acadia Pharmaceuticals (ACAD), Eli Lilly (LLY) 2:30 PM: ZS Pharma (ZSPH), Pfizer (PFE), Karyopharm Therapeutics (KPTI) 3:00 PM: Otonomy (OTIC) 3:30 PM: NPS Pharmaceuticals (NPSP), Accelerate Diagnostics (AXDX) 4:00 PM: Keryx Pharmaceuticals (KERX), Halozyme Therapeutics (HALO), GlaxoSmithKline (GSK), OPKO Health (OPK) Two companies in the headlines that are scheduled to present today are NPS Pharmaceuticals and Bristol-Myers Squibb. This weekend Shire (SHPG) announced they will acquire NPS for $5.2 Billion, or $46 a share. This was about a 10% premium to the previous day's close, but a significant premium over the average price of the last 45 trading sessions. Bristol-Myers Squibb announced that its drug Opdivo prolonged survival in patients with lung cancer. The study was stopped early because the study met endpoints before it was expected. Stopping a trial early for efficacy means the drug was very effective.
Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Posted In: Long IdeasNewsFDAM&ATrading Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...